Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan;11(1):180-181.
doi: 10.1177/1932296816654715. Epub 2016 Jul 9.

Rapid Benefits of Structured Optimization and Sensor-Augmented Insulin Pump Therapy in Adults With Type 1 Diabetes

Lalantha Leelarathna  1   2 , Hood Thabit  2   3 , Sara Hartnell  3 , Malgorzata E Willinska  2   4 , Sibylle Dellweg  5 , Carsten Benesch  5 , Julia K Mader  6 , Manuel Holzer  6 , Harald Kojzar  6 , Mark L Evans  2   3 , Sabine Arnolds  5 , Thomas R Pieber  6 , Roman Hovorka  2   4 ; AP@home Consortium
Affiliations
Randomized Controlled Trial

Rapid Benefits of Structured Optimization and Sensor-Augmented Insulin Pump Therapy in Adults With Type 1 Diabetes

Lalantha Leelarathna et al. J Diabetes Sci Technol. 2017 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RH reports having received speaker honoraria from Minimed Medtronic, Eli Lilly, BBraun, and Novo Nordisk, serving on advisory panel for Eli Lilly, Novo Nordisk and Merck, receiving license fees from BBraun and Medtronic; and having served as a consultant to BBraun and Profil. MEW has received license fees from Becton Dickinson and has served as a consultant to Beckton Dickinson. MLE reports having received speaker honoraria from Abbott Diabetes Care, Novo Nordisk and Animas, serving on advisory panels for Novo Nordisk, Abbott Diabetes Care, Medtronic, Roche and Cellnovo and holding stock options in Cellnovo. SH serves as a consultant for Novo-Nordisk and for the ONSET group, and reports having received speaker/training honoraria from Medtronic. RH and MEW report patents and patent applications. JKM reports having received speaker honoraria from AstraZeneca, NintaMed, NovoNordisk, Roche Diabetes Care, Sanofi, Takeda, and serving on advisory panel for MSD, Sanofi, and Boehringer Ingelheim. TRP is an advisory board member of Novo Nordisk A/S, a consultant for Roche, Novo Nordisk A/S, Eli Lilly & Co, Infineon, Carnegie Bank, and on speaker’s bureau of Novo Nordisk A/S and Astra Zeneca. HT, LL, SD, CB, MH, HK, and SA declare no competing financial interests exist.

Figures

Figure 1.
Figure 1.
Mean HbA1c(SD) at baseline, after optimization and post 3 months of sensor augmented pump therapy.
See this image and copyright information in PMC

References

    1. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015;373:2129-2140. - PMC - PubMed
    1. Leelarathna L, Dellweg S, Mader JK, et al. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open. 2014;4:e006075. - PMC - PubMed
    1. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-1476. - PubMed
    1. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155-3162. - PMC - PubMed